Background/Aims. Pancreatic ductal adenocarcinoma (PDA) has etiological association with chronic inflammation. Elevated circulating levels of inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1), are found in obese individuals. We hypothesized that serum MCP-1 levels are elevated in obese PDA patients. Methods. ELISA was used to analyze MCP-1 serum levels in PDA (n = 62) and intraductal papillary mucinous neoplasms (IPMN) (n = 27). Recursive partitioning statistical analysis investigated the relationship between log MCP-1 and clinicopathological parameters. Results. Log MCP-1 values were significantly (P < 0.05) elevated in patients with BMI ≥ 37.5. In patients with BMI < 37.5, average log MCP-1 values were significantly elevated in PDA patients when compared to IPMN patients. Within the IPMN group, higher log MCP-1 levels correlated with increased age. Recursive partitioning analysis of IPMN versus PDA revealed a strategy of predicting characteristics of patients who are more likely to have cancer. This strategy utilizes log MCP-1 as the primary factor and also utilizes smoking status, gender, and age. Conclusion. MCP-1 is a promising biomarker in pancreatic cancer. The potential of using MCP-1 to distinguish PDA from IPMN patients must be studied in larger populations to validate and demonstrate its eventual clinical utility.
Sullivan, Jennifer; Gong, Qiaoke; Hyslop, Terry; Lavu, Harish; Chipitsyna, Galina; Yeo, Charles; and Arafat, Hwyda A, "Serum monocyte chemoattractant protein-1 in pancreatic cancer." (2011). Department of Surgery Faculty Papers. Paper 81.
Medical Anatomy Commons, Medical Cell Biology Commons, Medical Pathology Commons, Medical Pharmacology Commons, Oncology Commons, Surgery Commons
This article has been peer reviewed. It was published in: Journal of Oncology.
The published version is available at DOI: 10.1155/2011/518394. Copyright © Hindawi Publishing.